The activation of NF-κB has been associated with resistance to different cell death strategies in GBM, and NF-κB-target genes (citokines, cell-cycle regulators, and anti-apoptotic proteins between others) have been proposed to influence the invasion capacity and resistance to chemotherapy [33]. This evidence concerns the gene NFKB1 and glioblastoma.